Long-acting beta-2 agonists
are used for the chronic maintenance of asthma, not for acute attacks, and are often administered in a fixed-dose combination with an inhaled corticosteroid, such as Advair Diskus (salmeterolgiuticasone).
More recently, long-acting beta-2 agonist
drugs (LABA) salmeterol and eformoterol have gained popularity in the management of asthma that is not well-controlled with short-acting beta agonist and inhaled corticosteroid therapy (ICS).
were shown to increase the cardiac repolar-izing current and have previously shown to increase QT dispersion (QTd) which is thought to represent regional differences in ventricular repolarization (1-4).
One approach is to treat this patient with a long-acting beta-2 agonist
such as salmeterol or formoterol around the clock.
The beta-2 agonist
use was reduced by 95%, and the corticosteroid inhaler was reduced by 92%.
Overall, the results indicate that daily use of an inhaled short-acting beta-2 agonist
was associated [odds ratio (OR) = 1.
The report compared the use of the newer anti-inflammatory drugs with the more conventional asthma drugs, such as theophylline and the newer bronchodilators known as beta-2 agonists
4 The World Short-Acting Beta-2 Agonist
(SABA) Market: Revenues ($bn) and Market Shares (%) by Leading Drugs, 2012 Table 4.
2 Key Products Marked Share (%) Within the Beta-2 Agonist
They also have a short-acting beta-2 agonist
available for quick relief when necessary.
A full trial and documented compliance with inhaled high-dose corticosteroids and long acting Beta-2 agonists
in addition to leukotriene receptor antagonists, theophyllines, oral corticosteroids and Beta-2 agonist
tablets and smoking cessation where applicable.
Pearl is rapidly advancing a pipeline of products including PT003, an inhaled, fixed-dose combination bronchodilator product comprised of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist
(LABA) delivered via a metered dose inhaler (HFA MDI); and PT010, a triple-combination product that combines the LAMA and LABA components of PT003 with an inhaled corticosteroid (ICS) for twice-daily administration from an HFA MDI for the treatment of severe COPD.
TABLE 17 PROJECTED MARKET FOR SHORT-ACTING BETA-2 AGONIST
announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003(GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist
The company has also successfully combined a nanogram-level GP dose with a previously established therapeutic dose of formoterol fumarate (FF), a long-acting beta-2 agonist